Solosec is an anti-bacterial drug owned by Lupin. It contains the active ingredient, secnidazole. Solosec was first authorized for market use on 15 September, 2017 and is available in granule oral dosage forms. The drug holds a total of 10 patents, none of which have expired.
The generic version of Solosec is expected to be available after 16 September, 2035. Drug patent challenges can be filed against Solosec from 15 September, 2026.
Solosec is used for the treatment of bacterial vaginosis in both adult women and female patients 12 years of age and older. It is also used for the treatment of trichomoniasis in both adults and patients 12 years of age and older.
Solosec holds a total of 10 patents. Various patents detail the use of its active ingredient, Secnidazole, for the treatment of bacterial vaginosis and trichomoniasis. The last patent is due to expire on 16 September, 2035. Solosec generic will be possible for release after this date. Below are the details of the patent: